Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Alimera Sciences stock

Own Alimera Sciences stock in just a few minutes.

Posted

Fact checked

Alimera Sciences, Inc is a drug manufacturers—specialty & generic business based in the US. Alimera Sciences shares (ALIM) are listed on the NASDAQ and all prices are listed in US Dollars. Alimera Sciences employs 122 staff and has a trailing 12-month revenue of around USD$54.8 million.

How to buy shares in Alimera Sciences

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Alimera Sciences. Find the stock by name or ticker symbol: ALIM. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Alimera Sciences reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Alimera Sciences, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Alimera Sciences. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Alimera Sciences share price

Use our graph to track the performance of ALIM stocks over time.

Alimera Sciences shares at a glance

Information last updated 2020-10-20.
52-week range USD$0.1973 - USD$9.98
50-day moving average USD$5.1999
200-day moving average USD$5.506
Wall St. target price USD$13.5
PE ratio 1.1297
Dividend yield N/A (0%)
Earnings per share (TTM) USD$0.303

Buy Alimera Sciences shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Alimera Sciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Alimera Sciences under- or over-valued?

Valuing Alimera Sciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Alimera Sciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Alimera Sciences's P/E ratio

Alimera Sciences's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 1x. In other words, Alimera Sciences shares trade at around 1x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Alimera Sciences's EBITDA

Alimera Sciences's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$1.1 million.

The EBITDA is a measure of a Alimera Sciences's overall financial performance and is widely used to measure a its profitability.

Alimera Sciences financials

Revenue TTM USD$54.8 million
Gross profit TTM USD$47.3 million
Return on assets TTM -1.94%
Return on equity TTM 0%
Profit margin -11.66%
Book value $-0.479
Market capitalisation USD$23.3 million

TTM: trailing 12 months

Shorting Alimera Sciences shares

There are currently 31,489 Alimera Sciences shares held short by investors – that's known as Alimera Sciences's "short interest". This figure is 15.6% down from 37,310 last month.

There are a few different ways that this level of interest in shorting Alimera Sciences shares can be evaluated.

Alimera Sciences's "short interest ratio" (SIR)

Alimera Sciences's "short interest ratio" (SIR) is the quantity of Alimera Sciences shares currently shorted divided by the average quantity of Alimera Sciences shares traded daily (recently around 16315.544041451). Alimera Sciences's SIR currently stands at 1.93. In other words for every 100,000 Alimera Sciences shares traded daily on the market, roughly 1930 shares are currently held short.

However Alimera Sciences's short interest can also be evaluated against the total number of Alimera Sciences shares, or, against the total number of tradable Alimera Sciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Alimera Sciences's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Alimera Sciences shares in existence, roughly 10 shares are currently held short) or 0.007% of the tradable shares (for every 100,000 tradable Alimera Sciences shares, roughly 7 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Alimera Sciences.

Find out more about how you can short Alimera Sciences stock.

Alimera Sciences share dividends

We're not expecting Alimera Sciences to pay a dividend over the next 12 months.

Have Alimera Sciences's shares ever split?

Alimera Sciences's shares were split on a 1:15 basis on 15 November 2019. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Alimera Sciences shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Alimera Sciences shares which in turn could have impacted Alimera Sciences's share price.

Alimera Sciences share price volatility

Over the last 12 months, Alimera Sciences's shares have ranged in value from as little as $0.1973 up to $9.98. A popular way to gauge a stock's volatility is its "beta".

ALIM.US volatility(beta: 2)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Alimera Sciences's is 1.9983. This would suggest that Alimera Sciences's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Alimera Sciences overview

Alimera Sciences, Inc., a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It focuses on diseases affecting the back of the eye or retina. The company offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness. Its ILUVIEN is inserted in the back of the patient's eye in a non-surgical procedure, which allows for a self-sealing wound by delivering a continuous microdose of the non-proprietary corticosteroid fluocinolone acetonide in the eye. The company has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of proprietary insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. It sells its products through sales force, as well as through distributors. The company serves physician offices, pharmacies, and hospitals. Alimera Sciences, Inc. was founded in 2003 and is headquartered in Alpharetta, Georgia.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site